Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are climbing more than 10% Thursday morning ahead of fourth-quarter results, scheduled to be reported on Friday, March 11, before the market opens.
The company's lead investigational product LOMECEL-B is in Phase 1 and 2 studies in various indications, including aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.
LGVN is at $7.85 currently. It has traded in the range of $2.84-$45 in the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.